Selecting high-risk early breast cancer patients: What to add to the number of metastatic nodes?
- 31 January 1996
- journal article
- Published by Elsevier BV in European Journal of Cancer
- Vol. 32 (1), 41-46
- https://doi.org/10.1016/0959-8049(95)00442-4
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- CMF vs alternating CMF/EV in the adjuvant treatment of operable breast cancer. A single centre randomised clinical trial (Naples GUN-3 study)British Journal of Cancer, 1995
- Pathologic findings from the national surgical adjuvant breast project (protocol 4): Discriminants for 15-year survivalCancer, 1993
- Pathologic correlates of prognosis in lymph node-positive breast carcinomasCancer, 1993
- High-dose chemotherapy in solid tumoursAnnals of Oncology, 1993
- « T » Category and Operable Breast Cancer PrognosisTumori Journal, 1989
- Relation of tumor size, lymph node status, and survival in 24,740 breast cancer casesCancer, 1989
- ADJUVANT THERAPY WITH TAMOXIFEN IN OPERABLE BREAST CANCER: 10 year results of the Naples (GUN) studyThe Lancet, 1988
- Long-term survival and prognostic factors in breast cancer patients with localized (no skin, muscle, or chest wall attachment) disease with and without positive lymph nodesCancer, 1986
- Long-term survival and prognostic factors in patients with regional breast cancer (skin, muscle, and/or chest wall attachment)Cancer, 1985
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958